REPL Stock Overview

A clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. More details

REPL fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 59.9% below our estimate of its fair value

Revenue is forecast to grow 61.8% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Replimune Group, Inc. Competitors

Xencor

NasdaqGM:XNCR

US$899.1m

Myriad Genetics

NasdaqGS:MYGN

US$919.5m

Rocket Pharmaceuticals

NasdaqGM:RCKT

US$934.1m

Zymeworks

NasdaqGS:ZYME

US$852.3m

Price History & Performance

Summary of share price highs, lows and changes for Replimune Group
Historical stock prices
Current Share Price	US$11.66
52 Week High	US$17.00
52 Week Low	US$4.92
Beta	1.3
1 Month Change	-17.34%
3 Month Change	-0.55%
1 Year Change	40.76%
3 Year Change	-26.14%
5 Year Change	30.96%
Change since IPO	-23.12%

Replimune: A Misunderstood Contender In Oncolytics

Feb 12

Recent updates

Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 23% Below Their Intrinsic Value Estimate

Jun 24

We're Not Very Worried About Replimune Group's (NASDAQ:REPL) Cash Burn Rate

Apr 04

Companies Like Replimune Group (NASDAQ:REPL) Are In A Position To Invest In Growth

Dec 16

Replimune: In The 'Buy Zone' Again

Oct 01

Shareholder Returns

	REPL	US Biotechs	US Market
7D	4.6%	-1.3%	0.3%
1Y	40.8%	-4.7%	9.0%

Return vs Industry: REPL exceeded the US Biotechs industry which returned -4.7% over the past year.

Return vs Market: REPL exceeded the US Market which returned 9% over the past year.

Price Volatility

Is REPL's price volatile compared to industry and market?
REPL volatility
REPL Average Weekly Movement	8.9%
Biotechs Industry Average Movement	10.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	17.4%
10% least volatile stocks in US Market	3.4%

Stable Share Price: REPL has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: REPL's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2015	331	Sush Patel	www.replimune.com

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors.

Replimune Group, Inc. Fundamentals Summary

How do Replimune Group's earnings and revenue compare to its market cap?
REPL fundamental statistics
Market cap	US$897.61m
Earnings (TTM)	-US$228.24m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.9x

P/E Ratio

Is REPL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
REPL income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$228.24m
Earnings	-US$228.24m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.96
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	9.5%

How did REPL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/17 09:54
End of Day Share Price	2025/03/14 00:00
Earnings	2024/12/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Replimune Group, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Peter Lawson	Barclays
Clarence Powell	BMO Capital Markets Equity Research
Evan Seigerman	BMO Capital Markets Equity Research

REPL Stock Overview

Rewards

Risk Analysis

Replimune Group, Inc. Competitors

NasdaqGM:XNCR

US$899.1m

NasdaqGS:MYGN

US$919.5m

NasdaqGM:RCKT

US$934.1m

NasdaqGS:ZYME

US$852.3m

Price History & Performance

Recent News & Updates

Replimune Group, Inc. Appoints Michael Goller to Its Board of Directors

Replimune: A Misunderstood Contender In Oncolytics

Replimune Group, Inc. Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

New major risk - Shareholder dilution

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

Price target increased by 11% to US$18.38

Recent updates

Replimune Group, Inc. Appoints Michael Goller to Its Board of Directors

Replimune: A Misunderstood Contender In Oncolytics

Replimune Group, Inc. Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

New major risk - Shareholder dilution

Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials

Price target increased by 11% to US$18.38

CEO & Director notifies of intention to sell stock

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $139.999007 million.

Replimune Group, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

New minor risk - Share price stability

Replimune Group, Inc. Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

Replimune Presents Late-Breaking Abstract Featuring Data from Ignyte Clinical Trial of Rp1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc 2024)

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-Pd1 Failed Melanoma At European Society for Medical Oncology Congress 2024

Replimune: Strong Data In A Highly Differentiated Space

Chief Financial Officer recently sold US$91k worth of stock

Is Replimune Group (NASDAQ:REPL) Using Debt Sensibly?

Consensus revenue estimates decrease by 50%, EPS upgraded

Replimune Group, Inc. Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

Price target increased by 8.2% to US$14.67

Replimune Group, Inc., Annual General Meeting, Sep 04, 2024

Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding

Chief Medical Officer notifies of intention to sell stock

Price target increased by 9.2% to US$14.56

Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma

New minor risk - Share price stability

Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

Replimune: Continuing To Justify The Bear Thesis (For Now)

Executive Chairman recently sold US$245k worth of stock

Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry?

Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Replimune Group, Inc. (NASDAQ:REPL)

Now 25% undervalued after recent price drop

Price target decreased by 64% to US$17.22

New minor risk - Share price stability

Replimune Group, Inc. Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failure Melanoma and Non-Melanoma Skin Cancers

Chief Medical Officer recently sold US$80k worth of stock

Replimune Group, Inc. Announces the Appointment of Emily Hill as Chief Financial Officer

New major risk - Revenue and earnings growth

Replimune Group, Inc Announces Appointment of Emily Hill as Chief Financial Officer

Chief Business Officer exercised options and sold US$250k worth of stock

Replimune Group, Inc. has completed a Follow-on Equity Offering in the amount of $6.7 million.

Replimune Group, Inc., Annual General Meeting, Sep 06, 2023

Replimune Group, Inc. Announces Sander Slootweg Will Depart from Its Board of Directors

Is Replimune Group (NASDAQ:REPL) A Risky Investment?

Chief Business Officer notifies of intention to sell stock

Chief Strategy Officer notifies of intention to sell stock

Replimune Group, Inc. Appoints Veleka R. Peeples-Dyer to Its Board of Directors

Replimune Group, Inc. Presents RP1 Data from the IGNYTE Anti-PD1 Failure Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates fall by 42%

CEO & Director recently sold US$323k worth of stock

No longer forecast to breakeven

Insufficient new directors

Is Replimune Group (NASDAQ:REPL) Using Debt In A Risky Way?